Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Department of Psychiatry, University of Campania «L. Vanvitelli», Naples, Italy (Италия); 2 South African Medical Research Council Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry and Neuroscience Institute, University of Cape Town, Cape Town South Africa (ЮАР); 3 School of Psychiatry, University of New South Wales, Sydney NSW, Australia (Австралия); 4 Department of Psychiatry and Human Behavior, Brown University School of Medicine, Rhode Island Hospital, Providence RI, USA (США); 5 Department of Psychiatry, University at Buffalo, State University of New York, Buffalo NY, USA (США); 6 University Psychiatric Centre KU Leuven, Kortenberg Belgium (Бельгия); 7 KU Leuven Department of Neurosciences, Leuven Belgium (Бельгия); 8 University Psychiatric Centre, University of Leuven, Leuven Belgium (Бельгия); 9 Department of Psychiatry, University of Toronto, Toronto Canada (Канада); 10Department of Psychology, University of Kentucky, Lexington KY, USA (США); 11Institute of Clinical Psychology and Psy- chotherapy, Technische Universität Dresden, Dresden, Germany (Германия); 12Department of Psychiatry and Psychotherapy, Ludwig Maximilans Uni- versität Munich, Munich, Germany (Германия).
Список исп. литературыСкрыть список 1. Maj M. Why the clinical utility of diagnostic categories in psychiatry is intrinsically limited and how we can use new approaches to complement them. World Psychiatry 2018;17:121-2. 2. Simon GE, Perlis RH. Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry 2010;167:1445-55. 3. Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-17. 4. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996;19:179-200. 5. National Institute for Health and Care Excellence. Depression in adults: recognition and management. London: National Institute for Health and Care Excellence, 2018. 6. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd ed. Washington: American Psychiatric Association, 2010. 7. American Psychiatric Association. Diagnostic and statistical manual of men-tal disorders, 5th ed. Arlington: American Psychiatric Association, 2013. 8. World Health Organization. ICD-11 guidelines. https://gcp. network/en/. 9. Rabinowitz J, Werbeloff N, Mandel FS et al. Initial depression severity and response to antidepressants v. placebo: patient-level data analysis from 34 randomised controlled trials. Br J Psychiatry 2016;209:427-8. 10. Driessen E, Cuijpers P, Hollon SD et al. Does pretreatment severity moder-ate the efficacy of psychological treatment of adult outpatient depression? A meta-analysis. J Consult Clin Psychol 2010;78:668-80. 11. Chekroud AM, Gueorguieva R, Krumholz HM et al. Reevaluating the efficacy and predictability of antidepressant treatments. A symptom clustering ap-proach. JAMA Psychiatry 2017;74:370-8. 12. Boschloo L, Bekhuis E, Weitz ES et al. The symptom-specific efficacy of an-tidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis. World Psychiatry 2019;18:183-91. 13.Chekroud AM, Zotti RJ, Shehzad Z et al. Cross-trial prediction of treatment outcome in depression: a machine learning approach. Lancet Psychiatry 2016;3:243-50. 14. Iniesta R, Malki K, Maier W et al. Combining clinical variables to optimize prediction of antidepressant treatment outcomes. J Psychiatr Res 2016;78:94-102 15. Kessler RC. The potential of predictive analytics to provide clinical decision support in depression treatment planning. Curr Opin Psychiatry 2018;31:32-9. 16. Howard L, Khalifeh H. Perinatal mental health: a review of progress and challenges. World Psychiatry 2020;19:313-27. 17. Zimmerman M, McGlinchey JB, Young D et al. Diagnosing major depres-sive disorder I. A psychometric evaluation of the DSM-IV symptom criteria. J Nerv Ment Dis 2006;194:158-63. 18. McGlinchey JB, Zimmerman M, Young D et al. Diagnosing major depres-sive disorder VIII. Are some symptoms better than others? J Nerv Ment Dis 2006:194:785-90. 19. Fried EI, Epskamp S, Nesse RM et al. What are «good» depression symptoms? Comparing the centrality of DSM and non-DSM symptoms of depression in a network analysis. J Affect Disord 2016;189:314-20. 20. Haroz EE, Ritchey M, Bass JK et al. How is depression experienced around the world? A systematic review of qualitative literature. Soc Sci Med 2017;183:151-62. 21. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62. 22. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9. 23. Beck AT, Ward CH, Mendelson M et al. An inventory for measuring depres-sion. Arch Gen Psychiatry 1961;4:561-71. 24. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401. 25. Rush AJ, Trivedi MH, Ibrahim HM et al. The 16-item Quick Inventory of De-pressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major de-pression. Biol Psychiatry 2003;54:573-83. 26. Rush AJ, Gullion CM, Basco MR et al. The Inventory of Depressive Symptom-atology (IDS): psychometric properties. Psychol Med 1996;26:477-86. 27. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965;12:63-70. 28. Fried EI. The 52 symptoms of major depression: lack of content overlap among seven common depression scales. J Affect Disord 2017;208:191-7. 29. Martin LA, Neighbors HW, Griffith DM. The experience of symptoms of depression in men vs women. Analysis of the National Comorbidity Survey Replication. JAMA Psychiatry 2013;70:1100-6. 30. Magovcevic M, Addis ME. The Masculine Depression Scale: development and psychometric evaluation. Psychol Men Masc 2008;9:117-32. 31. Reed GM, First MB, Kogan CS et al. Innovations and changes in the ICD-11 classification of mental, behavioural and developmental disorders. World Psychiatry 2019;18:3-19. 32. Uher R, Farmer A, Maier W et al. Measuring depression: comparison and integration of three scales in the GENDEP study. Psychol Med 2008;38:289-300. 33. Li Y, Aggen S, Shi S et al. The structure of the symptoms of major depres-sion: exploratory and confirmatory factor analysis in depressed Han Chinese women. Psychol Med 2014;44:1391-1401. 34. Fava M, Rush AJ, Alpert JE et al. Difference in treatment outcome in outpa-tients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008;165:342-51. 35. Davidson JR, Meoni P, Haudiquet V et al. Achieving remission with venlafax-ine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress Anxiety 2002;16:4-13. 36. Uher R, Perlis RH, Henigsberg N et al. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med 2012;42:967-80. 37. Uher R, Maier W, Hauser J et al. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. Br J Psychiatry 2009;194:252-9. 38. Kennedy SH, Lam RW, McIntyre RS et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Manage-ment of Adults with Major Depressive Disorder: Section 3. Pharmacological treatments. Can J Psychiatry 2016;61:540-60. 39. Kraemer HC. Discovering, comparing, and combining moderators of treat-ment on outcome after randomized clinical trials: a parametric approach. Stat Med 2013;32:1964-73. 40. Kessler RC, van Loo HM, Wardenaar KJ et al. Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder. Epide-miol Psychiatr Sci 2017;26:22-36. 41. Pedrelli P, Blais MA, Alpert JE et al. Reliability and validity of the Symptoms of Depression Questionnaire (SDQ). CNS Spectr 2014;19:535-46. 42. Dong M, Zeng LN, Lu L et al. Prevalence of suicide attempt in individuals with major depressive disorder: a meta-analysis of observational surveys. Psychol Med 2019;49:1691-1704. 43. Franklin JC, Ribeiro JD, Fox KR et al. Risk factors for suicidal thoughts and behaviors: a meta-analysis of 50 years of research. Psychol Bull 2017;143:187-232. 44. Posner K, Brown GK, Stanley B et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011;168:1266-77. 45.Trivedi MH, Wisniewski SR, Morris DW et al. Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. J Clin Psychiatry 2011;72:757-64. 46. Hirschfeld RMA, Williams JBW, Spitzer RL et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. J Clin Psychiatry 2000;157:1873-5. 47. Parker G, Fletcher K, Barrett M et al. Screening for bipolar disorder: the utility and comparative properties of the MSS and MDQ measures. J Affect Disord 2008;109:83-9. 48. Zimmerman M, Coryell W, Pfohl B et al. The validity of four definitions of en-dogenous depression. II. Clinical, demographic, familial, and psychosocial correlates. Arch Gen Psychiatry 1986;43:234-44. 49.Parker G, McCraw S, Blanch B et al. Discriminating melancholic and non-melancholic depression by prototypic clinical features. J Affect Disord 2013;144:199-207. 50. Melartin T, Leskela U, Rytsala H et al. Co-morbidity and stability of melan-cholic features in DSM-IV major depressive disorder. Psychol Med 2004;34:1443-52. 51. Coryell W. The facets of melancholia. Acta Psychiatr Scand 2007;115(Suppl. 433):31-6. 52. Brown WA. Treatment response in melancholia. Acta Psychiatr Scand 2007;115(Suppl. 433):125-9. 53. Cuijpers P, Weitz E, Lamers F et al. Melancholic and atypical depression as predictor and moderator of outcome in cognitive behavior therapy and pharmacotherapy for adult depression. Depress Anxiety 2017;34:246-56. 54. Perry PJ. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor an-tidepressants. J Affect Disord 1996;39:1-6. 55.Taylor MA, Fink M. Restoring melancholia in the classification of mood dis-orders. J Affect Disord 2008;105:1-14. 56. Amsterdam JD. Selective serotonin reuptake inhibitor efficacy in severe and melancholic depression. J Psychopharmacol 1998;12(Suppl. B):S99-111. 57.Malhi GS, Bassett D, Boyce P et al. Royal Australian and New Zealand Col-lege of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015;49:1087-206. 58. Maj M, Pirozzi R, Di Caprio EL. Major depression with mood-congruent psychotic features: a distinct diagnostic entity or a more severe subtype of depression? Acta Psychiatr Scand 1990;82:439-44. 59. Wijkstra J, Lijmer J, Burger H et al. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev 2015;7:CD004044. 60. First MB, Williams JBW, Karg RS et al. Structured Clinical Interview for DSM-5 – Research Version (SCID-5-RV). Arlington: American Psychiatric Publish-ing, 2015. 61. Zimmerman M, Chelminski I. A scale to screen for axis I disorders in psy-chiatric outpatients: performance of the Psychiatric Diagnostic Screening Questionnaire. Psychol Med 2006;36:1601-11. 62. Benazzi F. Reviewing the diagnostic validity and utility of mixed depression (depressive mixed states). Eur Psychiatry 2008;23:40-8. 63. Koukopoulos A, Sani G, Ghaemi SN. Mixed features of depression: why DSM-5 is wrong (and so was DSM-IV). Br J Psychiatry 2013;203:3-5. 64. Rosenblat JD, McIntyre RS. Treatment recommendations for DSM-5-defined mixed features. CNS Spectr 2017;22:147-54. 65. Stahl SM, Morrissette DA, Faedda G et al. Guidelines for the recognition and management of mixed depression. CNS Spectr 2017;22:203-19. 66. Young RC, Biggs JT, Ziegler VE et al. A rating scale for mania: reliability, valid-ity and sensitivity. Br J Psychiatry 1978;133:429-35. 67. Zimmerman M, Chelminski I, Young D et al. A clinically useful self-report measure of the DSM-5 mixed features specifier of major depressive disorder. J Affect Disord 2014;168:357-62. 68. Zimmerman M, Martin J, McGonigal P et al. Validity of the DSM-5 anxious distress specifier for major depressive disorder. Depress Anxiety 2019;36:31-8. 69. Papakostas G, Stahl S, Krishen A et al. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 stud-ies. J Clin Psychiatry 2008;69:1287-92. 70. Zimmerman M, Kerr S, Kiefer R et al. What is anxious depression? Overlap and agreement between different definitions. J Psychiatr Res 2019;109:133-8. 71. Zimmerman M, Chelminski I, Young D et al. A clinically useful self-report measure of the DSM-5 anxious distress specifier for major depressive disor-der. J Clin Psychiatry 2014;75:601-7. 72. Quitkin FM, Stewart JW, McGrath PJ et al. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome bounda-ries of selective MAOI responders. Am J Psychiatry 1988;145:306-11. 73. Łojko D, Rybakowski JK. Atypical depression: current perspectives. Neuro-psychiatr Dis Treat 2017;13:2447-56. 74. Meesters Y, Gordijn MC. Seasonal affective disorder, winter type: current in-sights and treatment options. Psychol Res Behav Manag 2016;9:317-27. 75.Pjrek E, Friedrich ME, Cambioli L et al. The efficacy of light therapy in the treatment of seasonal affective disorder: a meta-analysis of randomized con-trolled trials. Psychother Psychosom 2020;89:17-24. 76. Gartlehner G, Nussbaumer-Streit B, Gaynes BN et al. Second-generation an-tidepressants for preventing seasonal affective disorder in adults. Cochrane Database Syst Rev 2019;3:CD011268. 77. Forneris CA, Nussbaumer-Streit B, Morgan LC et al. Psychological thera-pies for preventing seasonal affective disorder. Cochrane Database Syst Rev 2019;5:CD011270. 78. Nussbaumer-Streit B, Forneris CA, Morgan LC et al. Light therapy for pre-venting seasonal affective disorder. Cochrane Database Syst Rev 2019;3:CD011269. 79. Rosenthal NE, Bradt GJ, Wehr TA. Seasonal Pattern Assessment Question-naire (SPAQ). Bethesda: National Institute of Mental Health, 1984. 80. Thompson C, Cowan A. The Seasonal Health Questionnaire: a preliminary validation of a new instrument to screen for seasonal affective disorder. J Af-fect Disord 2016;64:89-98. 81. Zimmerman M, Posternak MA, Friedman M et al. Which factors influence psychiatrists’ selection of an antidepressant? Am J Psychiatry 2004;161:1285-9. 82. Zimmerman M, Morgan TA, Stanton K. The severity of psychiatric disorders. World Psychiatry 2018;17:258-75. 83. O’Sullivan RL, Fava M, Agustin C et al. Sensitivity of the six-item Hamilton Depression Rating Scale. Acta Psychiatr Scand 1997;95:379-84. 84. Zimmerman M, Chelminski I, McGlinchey JB et al. A clinically useful depres-sion outcome scale. Compr Psychiatry 2008;49:131-40. 85. Kroenke K, Spitzer R, Williams J. The PHQ-9. Validity of a brief depression severity measure. J Gen Int Med 2001;16:606-13. 86. Zimmerman M, Martinez J, Friedman M et al. How can we use depression severity to guide treatment selection when measures of depression catego-rize patients differently? J Clin Psychiatry 2012;73:1287-91. 87. Khan A, Leventhal RM, Khan SR et al. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administra-tion database. J Clin Psychopharmacol 2002;22:40-5. 88. Kirsch I, Deacon BJ, Huedo-Medina TB et al. Initial severity and antidepres-sant benefits: a meta-analysis of data submitted to the Food and Drug Ad-ministration. PLoS Med 2008;5:e45. 89. Mosca D, Zhang M, Prieto R et al. Efficacy of desvenlafaxine compared with placebo in major depressive disorder patients by age group and severity of depression at baseline. J Clin Psychopharmacol 2017;37:182-92. 90. Weitz ES, Hollon SD, Twisk J et al. Baseline depression severity as modera-tor of depression outcomes between cognitive behavioral therapy vs phar-macotherapy: an individual patient data meta-analysis. JAMA Psychiatry 2015;72:1102-9. 91. Lorenzo-Luaces L, Zimmerman M, Cuijpers P. Are studies of psychothera-pies for depression more or less generalizable than studies of antidepres-sants? J Affect Disord 2018;234:8-13. 92. Guo T, Xiang YT, Xiao L et al. Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters. Am J Psychiatry 2015;172:1004-13. 93. Yeung AS, Jing Y, Brenneman SK et al. Clinical Outcomes in Measurement-based Treatment (COMET): a trial of depression monitoring and feedback to primary care physicians. Depress Anxiety 2012;29:865-73. 94. McIntyre RS, Cha DS, Soczynska JK et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treat-ment interventions. Depress Anxiety 2013;30:515-27. 95. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med 2011;41:1165-74. 96. Rock PL, Roiser JP, Riedel WJ et al. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med 2014;44:2029-40. 97. McIntyre RS, Soczynska JZ, Woldeyohannes HO et al. The impact of cognitive impairment on perceived workforce performance: results from the Interna-tional Mood Disorders Collaborative Project. Compr Psychiatry 2015;56:279-82. 98. McIntyre RS, Anderson N, Baune BT et al. Expert consensus on screening and assessment of cognition in psychiatry. CNS Spectr 2019;24:154-62. 99. Millan MJ, Agid Y, Brüne M et al. Cognitive dysfunction in psychiatric dis-orders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 2012;11:141-68. 100. Gorwood P, Corruble E, Falissard B et al. Toxic effects of depression on brain function: impairment of delayed recall and the cumulative length of depres-sive disorder in a large sample of depressed outpatients. Am J Psychiatry 2008;165:731-9. 101. Roddy DW, Farrell C, Doolin K et al. The hippocampus in depression: more than the sum of its parts? Advanced hippocampal substructure segmenta-tion in depression. Biol Psychiatry 2019;85:487-97. 102. Zuckerman H, Pan Z, Park C et al. Recognition and treatment of cognitive dysfunction in major depressive disorder. Front Psychiatry 2018;9:655. 103. Harrison JE, Lam RW, Baune BT et al. Selection of cognitive tests for trials of therapeutic agents. Lancet Psychiatry 2016;3:499. 104. McIntyre RS, Best MW, Bowie CR et al. The THINC-integrated tool (THINC-it) screening assessment for cognitive dysfunction: validation in patients with major depressive disorder. J Clin Psychiatry 2017;78:873-81. 105. Mansur RB, Cha DS, Woldeyohannes HO et al. Diabetes mellitus and distur-bances in brain connectivity: a bidirectional relationship? Neuromolecular Med 2014;16:658-68. 106. Hammar Å, Semkovska M, Borgen IMH et al. A pilot study of cognitive reme-diation in remitted major depressive disorder patients. Appl Neuropsychol Adult (in press). 107. Listunova L, Bartolovic M, Kienzle J et al. Predictors of cognitive remediation therapy improvement in (partially) remitted unipolar depression. J Affect Disord 2020;264:40-9. 108. Brondino N, Rocchetti M, Fusar-Poli L et al. A systematic review of cognitive effects of exercise in depression. Acta Psychiatr Scand 2017;135:285-95. 109. Abdel Latif A, Nasreldin M, Abdel Kader A et al. A randomized study com-paring the short-term neurocognitive outcome of electroconvulsive therapy versus repetitive transcranial magnetic stimulation in the treatment of pa-tients with depression. J Psychiatr Pract 2020;26:23-36. 110. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol 2014;17:1557-67. 111. Rosenblat JD, Kakar R, McIntyre RS. The cognitive effects of antidepressants in major depressive disorder: a systematic review and meta-analysis of ran-domized clinical trials. Int J Neuropsychopharmacol 2015;19:pyv082. 112. Connolly SL, Alloy LB. Rumination interacts with life stress to predict depres-sive symptoms: an ecological momentary assessment study. Behav Res Ther 2017;97:86-95. 113. Demyttenaere K, Enzlin P, Dewé W et al. Compliance with antidepressants in a primary care setting, 2: The influence of gender and type of impairment. J Clin Psychiatry 2001;62:34-7. 114. Zimmerman M, McGlinchey JB, Posternak MA et al. How should remission from depression be defined? The depressed patient’s perspective. Am J Psy-chiatry 2006;163:148-50. 115. Demyttenaere K, Donneau AF, Albert A et al. What is important in being cured from depression? Discordance between physicians and patients (1). J Affect Disord 2015;174:390-6. 116. De Fruyt J, Demyttenaere K. Quality of life measurement in antidepressant trials: is there an added value? Psychother Psychosom 2009;78:212-9. 117. Theofilou P. Quality of life: definition and measurement. Eur J Psychol 2013;9:150-62. 118. Moos RH, Nichol AC, Moos BS. Global Assessment of Functioning ratings and the allocation and outcomes of mental health services. Psychiatr Serv 2002;53:730-7. 119. RAND Health Care. 36-Item Short Form Survey (SF-36). www.rand.org. 120. World Health Organization. WHO Disability Assessment Schedule 2.0 (WHODAS 2.0). www.who.int. 121. World Health Organization. International Classification of Functioning, Dis-ability and Health (ICF). www.who.int. 122. World Health Organization. Model Disability Survey. www.who.int. 123. Endicott J, Nee J, Harrison W et al. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321-6. 124. Demyttenaere K, Mortier P, Kiekens G et al. Is there enough «interest in and pleasure in» the concept of depression? The development of the Leuven Af-fect and Pleasure Scale (LAPS). CNS Spectr 2019;24:265-74. 125. Organisation for Economic Co-operation and Development (OECD). Guide-lines on measuring subjective well-being. www.oecd.org. 126. Skantze K, Malm U. A new approach to facilitation of working alliances based on patients’ quality of life goals. Nord J Psychiatry 1994;48:37-55. 127. Carpiniello B, Lai GL, Pariante CM et al. Symptoms, standards of living and subjective quality of life: a comparative study of schizophrenic and de-pressed out-patients. Acta Psychiatr Scand 1997;96:235-41. 128. Demyttenaere K, Donneau AF, Albert A et al. What is important in being cured from depression: does discordance between physicians and patients matter? (2). J Affect Disord 2015;174:372-7. 129. Barry MJ, Edgman-Levitan S. Shared decision making – the pinnacle of pa-tient-centered care. N Engl J Med 2012;366:780-1. 130. Cuijpers P. Targets and outcomes of psychotherapies for mental disorders: an overview. World Psychiatry 2019;18:276-85.1 31. Fava GA, Kellner R. Staging: a neglected dimension in psychiatric classifica-tion. Acta Psychiatr Scand 1993;87:225-30. 132. Cosci F, Fava GA. Staging of mental disorders: systematic review. Psychother Psychosom 2013;82:20-34. 133. Detre TP, Jarecki H. Modern psychiatric treatment. Philadelphia: Lippincott, 1971. 134. Klein DN, Shankman SA, Rose S. Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. Am J Psy-chiatry 2006;163:872-80. 135. Guidi J, Tomba E, Cosci F et al. The role of staging in planning psychothera-peutic interventions in depression. J Clin Psychiatry 2017;78:456-63. 136. Guidi J, Tomba E, Fava GA. The sequential integration of pharmacotherapy and psychotherapy in the treatment of major depressive disorder: a meta-analysis of the sequential model and a critical review of the literature. Am J Psychiatry 2016;173:128-37. 137. Von Wolff A, Holzel LP, Westphal A et al. Combination of pharmacotherapy and psychotherapy in the treatment of chronic depression: a systematic re-view and meta-analysis. BMC Psychiatry 2012;12:61. 138. Thase ME, Rush AJ. When at first you don’t succeed: sequential strategies for antidepressant non-responders. J Clin Psychiatry 1997;58:23-9. 139. Souery D, Amsterdam J, de Montigny C et al. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychophar-macol 1999;9:83-91. 140. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psy-chiatry 2003;53:649-59. 141. Fekadu A, Wooderson S, Donaldson C et al. A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method. J Clin Psychiatry 2009;70:177-84. 142. Widiger TA (ed). The Oxford handbook of the five-factor model. New York: Oxford University Press, 2017. 143. Tackett JL, Lahey B. Neuroticism. In: Widiger TA (ed). The Oxford handbook of the five factor model. New York: Oxford University Press, 2017:39-56. 144. Widiger T, Oltmanns JR. Neuroticism is a fundamental domain of person-ality with enormous public health implications. World Psychiatry 2017;16:144-5. 145. Sauer-Zavala S, Wilner JG, Barlow DH. Addressing neuroticism in psycho-logical treatment. Personal Disord 2017;8:191-8. 146. Mullins-Sweatt SN, Hopwood CJ, Chmielewski M et al. Treatment of person-ality pathology through the lens of the hierarchical taxonomy of psychopa-thology: developing a research agenda. Pers Ment Health 2020;14:123-41. 147. Presnall J. Disorders of personality: clinical treatment from a five factor mod-el perspective. In: Widiger TA, Costa PT (eds). Personality disorders and the five-factor model of personality. Washington: American Psychological Asso-ciation, 2013:409-32. 148. Bagby RM, Quilty LC, Segal ZV et al. Personality and differential treatment response in major depression: a randomized controlled trial comparing cognitive-behavioural therapy and pharmacotherapy. Can J Psychiatry 2008;53:361-70. 149. Mulder RT, Horwood J, Tyrer P et al. Validating the proposed ICD-11 do-mains. Pers Ment Health 2016;10:84-95. 150. Dixon-Gordon KL, Turner BJ, Chapman AL. Psychotherapy for personality disorders. Int Rev Psychiatry 2011;23:282-302. 151. Cuijpers P, Reynolds CF 3rd, Donker T et al. Personalized treatment of adult depression: medication, psychotherapy, or both? A systematic review. De-press Anxiety 2012;29:855-64. 152. Joyce PR, McKenzie JM, Carter JD et al. Temperament, character and person-ality disorders as predictors of response to interpersonal psychotherapy and cognitive-behavioural therapy for depression. Br J Psychiatry 2007;190:503-8. 153. Costa PT, McCrae RR. Revised NEO Personality Inventory (NEO PI-R) and NEO Five-Factor Inventory (NEO-FFI) professional manual. Odessa: Psy-chological Assessment Resources, 1992. 154. Goldberg LR, Johnson JA, Eber HW et al. The international personality item pool and the future of public-domain personality measures. J Res Pers 2006;40:84-96. 155. Mullins-Sweatt SN, Jamerson JE, Samuel DB et al. Psychometric properties of an abbreviated instrument of the five-factor model. Assessment 2006;13:119-37. 156. Soto CJ, John OP. The next Big Five Inventory (BFI-2): developing and assess-ing a hierarchical model with 15 facets to enhance bandwidth, fidelity, and predictive power. J Pers Soc Psychol 2017;113:117-43. 157. Krueger RF, Derringer J, Markon KE et al. Initial construction of a mala-daptive personality trait model and inventory for DSM-5. Psychol Med 2012;42:1879-90. 158. Oltmanns JR, Widiger TA. A self-report measure for the ICD-11 dimensional trait model proposal: the Personality Inventory for ICD-11. Psychol Assess 2018;30:154-69. 159. Bagby RM, Farvolden P. The Personality Diagnostic Questionnaire-4 (PDQ-4). In: Hilsenroth MJ, Segal DL, Hersen M (eds). Comprehensive handbook of psychological assessment, Vol. 2. New York: Wiley, 2004:122-33. 160. Widiger TA, Smith GT. Personality and psychopathology. In: John OP, Robins R, Pervin LA (eds). Handbook of personality: theory and research, 3rd ed. New York: Guilford, 2008:743-69. 161. Copeland WE, Shanahan L, Costello J et al. Childhood and adolescent psy-chiatric disorders as predictors of young adult disorders. Arch Gen Psychia-try 2009;66:764-72. 162. Kendler KS. Major depression and generalised anxiety disorder: same genes, (partly) different environments – Revisited. Br J Psychiatry 1996;168(Suppl. 30):68-75. 163. Spitzer RL, Kroenke K, Williams JBW et al. A brief measure for assessing gen-eralized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092-7. 164. Meyer TJ, Miller ML, Metzger R et al. Development and validation of the Penn State Worry Questionnaire. Behav Res Ther 1990;6:487-95. 165. Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141-73. 166. Goodman WK, Price LH, Rasmussen SA et al. The Yale-Brown Obsessive-Compulsive Scale: II. Validity. Arch Gen Psychiatry 1989;46:1012-6. 167. Foa EB. Posttraumatic Stress Diagnostic Scale: manual. Minneapolis: Na-tional Computer Systems, 1995. 168. Conners CK, Erhardt D, Sparrow EP. Conners Adult ADHD Rating Scales (CAARS). North Tonawanda: Multi-Health Systems, 1999. 169. Babor TF, Higgins-Biddle JC, Saunders JB et al. The Alcohol Use Disorders Identification Test. Guidelines for use in primary care, 2nd ed. Geneva: World Health Organization, 2001. 170. Skinner HA. The drug abuse screening test. Addict Behav 1982;7:363-71. 171. De Hert M, Correll CU, Bobes J et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52-77. 172. Correll CU, Detraux J, De Lepeleire J et al. Effects of antipsychotics, anti-depressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry 2015;14:119-36. 173. Firth J, Siddiqi N, Koyanagi A et al. The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. Lancet Psychiatry 2019;6:675-712. 174. De Hert M, Detraux J. Reversing the downward spiral for people with severe mental illness through educational innovations. World Psychiatry 2017;16:41-2. 175. Vancampfort D, Correll CU, Wampers M et al. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables. Psychol Med 2014;44:2017-28. 176. De Hert M, Cohen D, Bobes J et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry 2011;10:138-51. 177. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: ex-ecutive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2018;138:e426-83. 178. De Hert M, Detraux J, Vancampfort D. The intriguing relationship between coronary heart disease and mental disorders. Dialogues Clin Neurosci 2018;20:31-40. 179. Correll CU, Solmi M, Veronese N et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe men-tal illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 2017;16:163-80. 180. Yusuf S, Joseph P, Rangarajan S et al. Modifiable risk factors, cardiovascular disease, and mortality in 155,722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. Lan-cet 2020;395:795-808. 181. Rosengren A, Hawken S, Ounpuu S et al. Association of psychosocial risk fac-tors with risk of acute myocardial infarction in 11119 cases and 13648 con-trols from 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:953-62. 182. Garg N, Muduli SK, Kapoor A et al. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recom-mended statin uses. Indian Heart J 2017;69:458-63. 183. WHO CVD Risk Chart Working Group. World Health Organization cardio-vascular disease risk charts: revised models to estimate risk in 21 global re-gions. Lancet Glob Health 2019;7:e1332-45. 184. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017;357:j2099. 185. Vancampfort D, Mitchell AJ, De Hert M et al. Type 2 diabetes in patients with major depressive disorder: a meta-analysis of prevalence estimates and pre-dictors. Depress Anxiety 2015;32:763-73. 186. UK National Centre for Smoking Cessation and Training. Training and as-sessment programme. www.ncsct.co.uk. 187. Firth J, Stubbs B, Teasdale SB et al. Diet as a hot topic in psychiatry: a popu-lation-scale study of nutritional intake and inflammatory potential in severe mental illness. World Psychiatry 2018;17:365-7. 188. Gates J, Killackey E, Phillips L et al. Mental health starts with physical health: current status and future directions of non-pharmacological interventions to improve physical health in first-episode psychosis. Lancet Psychiatry 2015;2:726-42. 189. Centers for Disease Control and Prevention. National Diabetes Prevention Programme. www.cdc.gov. 190. Torous J, Andersson G, Bertagnoli A et al. Towards a consensus around standards for smartphone apps and digital mental health. World Psychiatry 2019;18:97-8. 191. Flint J, Kendler K. The genetics of major depression. Neuron 2014;81:484-503. 192. Kendler KS. The diagnostic validity of melancholic major depression in a population-based sample of female twins. Arch Gen Psychiatry 1997;54:299-304. 193. Franchini L, Serretti A, Gasperini M et al. Familial concordance of fluvoxam-ine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 1998;32:255-9. 194. Sugawara H, Sakamoto K, Harada T. Prediction of efficacy of lithium aug-mentation for treatment-resistant depression. J Affect Disord 2010;125:165-8. 195. Nurnberger JI, Blehar MC, Kaufmann CA et al. Diagnostic Interview for Ge-netic Studies: rationale, unique features and training: NIMH Genetics initia-tive. Arch Gen Psychiatry 1994;51:849-59. 196. Chapman TF, Mannuzza S, Klein DF et al. Effects of informant mental disor-der on psychiatric family history data. Am J Psychiatry 1994;151:574-9. 197. Weissman MM, Wickramaratne P, Adams P et al. Brief screening for family psychiatric history: the Family History Screen. Arch Gen Psychiatry 2000;57:675-82. 198. Li M, D’Arcy C, Meng X. Maltreatment in childhood substantially increases the risk of adult depression and anxiety in prospective cohort studies: sys-tematic review, meta-analysis, and proportional attributable fractions. Psy-chol Med 2016;46:717-30. 199. Lippard ETC, Nemeroff CB. The devastating clinical consequences of child abuse and neglect: increased disease vulnerability and poor treatment re-sponse in mood disorders. Am J Psychiatry 2020;177: 20-36. 200. Mandelli L, Petrelli C, Serretti A. The role of specific early trauma in adult depression: a meta-analysis of published literature. Childhood trauma and adult depression. Eur Psychiatry 2015;30: 665-80. 201. Infurna MR, Reichl C, Parzer P et al. Associations between depression and specific childhood experiences of abuse and neglect: a meta-analysis. J Af-fect Disord 2016;190:47-55. 202. Yap MB, Pilkington PD, Ryan SM et al. Parental factors associated with de-pression and anxiety in young people: a systematic review and meta-analy-sis. J Affect Disord 2014;156:8-23. 203. Herzog JI, Schmahl C. Adverse childhood experiences and the consequenc-es on neurobiological, psychosocial, and somatic conditions across the life-span. Front Psychiatry 2018;9:420. 204. Jaffee SR. Child maltreatment and risk for psychopathology in childhood and adulthood. Annu Rev Clin Psychol 2017;13:525-51. 205. McLaughlin KA, Sheridan MA, Nelson CA. Neglect as a violation of species-expectant experience: neurodevelopmental consequences. Biol Psychiatry 2017;82:462-71. 206. Braithwaite EC, O’Connor RM, Degli-Esposti M et al. Modifiable predictors of depression following childhood maltreatment: a systematic review and meta-analysis. Transl Psychiatry 2017;7:e1162. 207. Kessler RC, McLaughlin KA, Green JG et al. Childhood adversities and adult psychopathology in the WHO World Mental Health Surveys. Br J Psychiatry 2010;197:378-85. 208. Bifulco A, Brown GW, Harris TO. Childhood Experience of Care and Abuse (CECA): a retrospective interview measure. J Child Psychol Psychiatry 1994;35:1419-35. 209. Bifulco A, Bernazzani O, Moran PM et al. The Childhood Experience of Care and Abuse Questionnaire (CECA.Q): validation in a community series. Br J Clin Psychol 2005;44:563-81. 210. Bernstein DP, Stein J, Newcomb M et al. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Negl 2003;27:169-90. 211. Louis JP, Wood AM, Lockwood G. Psychometric validation of the Young Parenting Inventory – Revised (YPI-R2): replication and extension of a com-monly used parenting scale in Schema Therapy (ST) research and practice. PLoS One 2018;13:e0205605. 212. Phillips K, Brockman R, Bailey PE et al. Young Schema Questionnaire – Short Form Version 3 (YSQ-S3): preliminary validation in older adults. Aging Ment Health 2019;23:140-7. 213. Gibbons MBC, Gallop R, Thompson D et al. Predictors of treatment at-tendance in cognitive and dynamic therapies for major depressive disor-der delivered in a community mental health setting. J Consult Clin Psychol 2019;87:745-55. 214. Dominguez S, Drummond P, Gouldthorp B et al. A randomized controlled trial examining the impact of individual trauma-focused therapy for individ-uals receiving group treatment for depression. Psychol Psychother (in press). 215. Nanni V, Uher R, Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry 2012;169:141-51. 216. Christensen MC, Florea I, Loft H et al. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. J Af-fect Disord 2020;263:258-66. 217. Talbot NL, Chaudron LH, Ward EA et al. A randomized effectiveness trial of interpersonal psychotherapy for depressed women with sexual abuse histo-ries. Psychiatr Serv 2011;62:374-80.218. 218.Kohler CA, Evangelou E, Stubbs B et al. Mapping risk factors for depression across the lifespan: an umbrella review of evidence from meta-analyses and Mendelian randomization studies. J Psychiatr Res 2018;103:189-207. 219. Madsen IEH, Nyberg ST, Magnusson Hanson LL et al. Job strain as a risk fac-tor for clinical depression: systematic review and meta-analysis with addi-tional individual participant data. Psychol Med 2017;47:1342-56. 220. Seabrook EM, Kern ML, Rickard NS. Social networking sites, depression, and anxiety: a systematic review. JMIR Ment Health 2016;3:e50. 221. Wang X, Li Y, Fan H. The associations between screen time-based sedentary behavior and depression: a systematic review and meta-analysis. BMC Pub-lic Health 2019;19:1524. 222. Rautio N, Filatova S, Lehtiniemi H et al. Living environment and its relation-ship to depressive mood: a systematic review. Int J Soc Psychiatry 2018;64:92-103. 223. Clark C, Crumpler C, Notley AH. Evidence for environmental noise effects on health for the United Kingdom Policy Context: a systematic review of the effects of environmental noise on mental health, wellbeing, quality of life, 292 World Psychiatry 19:3 – October 2020 cancer, dementia, birth, reproductive outcomes, and cognition. Int J Environ Res Public Health 2020;17(2). 224. Braithwaite I, Zhang S, Kirkbride JB et al. Air pollution (particulate matter) exposure and associations with depression, anxiety, bipolar, psychosis and suicide risk: a systematic review and meta-analysis. Environ Health Perspect 2019;127:126002. 225. Thompson R, Hornigold R, Page L et al. Associations between high ambient temperatures and heat waves with mental health outcomes: a systematic re-view. Public Health 2018;161:171-91. 226. Bottino SMB, Bottino CMC, Regina CG et al. Cyberbullying and adolescent mental health: systematic review. Cad Saude Publica 2015;31:463-75. 227. Barnett A, Zhang CJP, Johnston JM et al. Relationships between the neigh-borhood environment and depression in older adults: a systematic review and meta-analysis. Int Psychogeriatr 2018;30:1153-76. 228. Chau R, Kissane DW, Davison TE. Risk factors for depression in long-term care: a systematic review. Clin Gerontol 2019;42:224-37. 229. Pinquart M, Sorensen S. Associations of caregiver stressors and uplifts with subjective well-being and depressive mood: a meta-analytic comparison. Aging Ment Health 2004;8:438-49. 230. Yim IS, Tanner Stapleton LR, Guardino CM et al. Biological and psychosocial predictors of postpartum depression: systematic review and call for integra-tion. Annu Rev Clin Psychol 2015;11:99-137. 231. Singh A, Daniel L, Baker E et al. Housing disadvantage and poor mental health: a systematic review. Am J Prev Med 2019;57:262-72. 232. Foo SQ, Tam WW, Ho CS et al. Prevalence of depression among migrants: a systematic review and meta-analysis. Int J Environ Res Public Health 2018;15:1986. 233. Valentine SE, Shipherd JC. A systematic review of social stress and mental health among transgender and gender non-conforming people in the Unit-ed States. Clin Psychol Rev 2018;66:24-38. 234. Scherer N, Verhey I, Kuper H. Depression and anxiety in parents of children with intellectual and developmental disabilities: a systematic review and meta-analysis. PLoS One 2019;14:e0219888. 235. Brown GW, Harris TO, Hepworth C. Life events and endogenous depression. A puzzle reexamined. Arch Gen Psychiatry 1994;51:525-34. 236. Dohrenwend BS, Krasnoff L, Askenasy AR et al. Exemplification of a method for scaling life events: the Peri Life Events Scale. J Health Soc Behav 1978;19:205-29. 237. Brugha TS, Cragg D. The List of Threatening Experiences: the reliability and validity of a brief life events questionnaire. Acta Psychiatr Scand 1990;82:77-81. 238. Butjosa A, Gómez-Benito J, Myin-Germeys I et al. Development and vali-dation of the Questionnaire of Stressful Life Events (QSLE). J Psychiatr Res 2017;95:213-23. 239. Yang YS, Ryu GW, Choi M. Methodological strategies for ecological momen-tary assessment to evaluate mood and stress in adult patients using mobile phones: systematic review. JMIR Mhealth Uhealth 2019;7:e11215. 240. Colombo D, Fernández-Álvarez J, Patané A et al. Current state and future di-rections of technology-based ecological momentary assessment and inter-vention for major depressive disorder: a systematic review. J Clin Med 2019;8:465. 241. Myin-Germeys I, Kasanova Z, Vaessen T et al. Experience sampling method-ology in mental health research: new insights and technical developments. World Psychiatry 2018;17:123-32. 242. McFarquhar T, Luyten P, Fonagy P. Changes in interpersonal problems in the psychotherapeutic treatment of depression as measured by the Inventory of Interpersonal Problems: a systematic review and meta-analysis. J Affect Dis-ord 2018;226:108-23.243. 243. van der Noordt M, IJzelenberg H, Droomers M et al. Health effects of em-ployment: a systematic review of prospective studies. Occup Environ Med 2014;71:730-6. 244. Cairns KE, Yap MB, Pilkington PD et al. Risk and protective factors for de-pression that adolescents can modify: a systematic review and meta-analysis of longitudinal studies. J Affect Disord 2014;169:61-75. 245. Ozer EJ, Lavi I, Douglas L et al. Protective factors for youth exposed to vio-lence in their communities: a review of family, school, and community mod-erators. J Clin Child Adolesc Psychol 2017;46:353-78. 246. Becares L, Dewey ME, Das-Munshi J. Ethnic density effects for adult mental health: systematic review and meta-analysis of international studies. Psychol Med 2018;48:2054-72. 247. Perez E, Braën C, Boyer G et al. Neighbourhood community life and health: a systematic review of reviews. Health Place 2019;61:102238. 248. Lassale C, Batty GD, Baghdadli A et al. Healthy dietary indices and risk of de-pressive outcomes: a systematic review and meta-analysis of observational studies. Mol Psychiatry 2019;24:965-86. 249. Gobbi G, Atkin T, Zytynski T et al. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood: a sys-tematic review and meta-analysis. JAMA Psychiatry 2019;76:426-34. 250. Kandola A, Ashdown-Franks G, Stubbs B et al. The association between cardiorespiratory fitness and the incidence of common mental health dis-orders: a systematic review and meta-analysis. J Affect Disord 2019;257:748-57. 251. Ni PK, Siew Lin SK. The role of family and friends in providing social support towards enhancing the wellbeing of postpartum women: a comprehensive systematic review. JBI Libr Syst Rev 2011;9:313-70. 252. Hall WJ. Psychosocial risk and protective factors for depression among les-bian, gay, bisexual, and queer youth: a systematic review. J Homosex 2018;65:263-316. 253. Nesse RM. Good reasons for bad feelings: insights from the frontier of evolu-tionary psychiatry. New York: Dutton, 2019. 254. Windle G, Bennett KM, Noyes J. A methodological review of resilience meas-urement scales. Health Qual Life Outcomes 2011;9:8. 255. Connor KM, Davidson JR. Development of a new resilience scale: the Con-nor-Davidson Resilience Scale (CD-RISC). Depress Anxiety 2003;18:76-82. 256. Campbell-Sills L, Stein MB. Psychometric analysis and refinement of the Connor-Davidson Resilience Scale (CD-RISC): validation of a 10-item meas-ure of resilience. J Trauma Stress 2007;20:1019-28. 257. Smith BW, Dalen J, Wiggins K et al. The brief resilience scale: assessing the ability to bounce back. Int J Behav Med 2008;15:194-200. 258. Zimet GD, Powell SS, Farley GK et al. Psychometric characteristics of the Multidimensional Scale of Perceived Social Support. J Pers Assess 1990;55:610-7. 259. Adler NE, Epel ES, Castellazzo G et al. Relationship of subjective and objec-tive social status with psychological and physiological functioning: prelimi-nary data in healthy white women. Health Psychol 2000;19:586-92. 260. Firth J, Marx W, Dash S et al. The effects of dietary improvement on symp-toms of depression and anxiety: a meta-analysis of randomized controlled trials. Psychosom Med 2019;81:265-80. 261. Reynolds CF 3rd. Building resilience through psychotherapy. World Psychia-try 2019;18:289-91. 262. Chmitorz A, Kunzler A, Helmreich I et al. Intervention studies to foster resil-ience – A systematic review and proposal for a resilience framework in future intervention studies. Clin Psychol Rev 2018;59:78-100. 263. Joyce S, Shand F, Tighe J et al. Road to resilience: a systematic review and meta-analysis of resilience training programmes and interventions. BMJ Open 2018;8:e017858. 264. Hofmann SG, Sawyer AT, Witt AA et al. The effect of mindfulness-based therapy on anxiety and depression: a meta-analytic review. J Consult Clin Psychol 2010;78:169-83. 265. Bai Z, Luo S, Zhang L et al. Acceptance and Commitment Therapy (ACT) to reduce depression: a systematic review and meta-analysis. J Affect Disord 2020;260:728-37. 266. Hofmann SG, Hayes SC. Therapeutic change processes link and clarify tar-gets and outcomes. World Psychiatry 2019;18:287-8. 267. Beck AT. Depression: clinical, experimental and theoretical aspects. New York: Harper & Row, 1967. 268. Beck AT, Rush AJ, Shaw BF et al. Cognitive therapy of depression. New York: Guilford, 1979. 269. Wright JH, Brown GK, Thase ME et al. Learning cognitive-behavior therapy, 2nd ed. Arlington: American Psychiatric Publishing, 2017. 270. Beck AT, Brown G, Steer RA et al. Factor analysis of Dysfunctional Attitude Scale in a clinical population. Psychol Assess 1991;3:478-83. 271. LeMoult J, Gotlib IH. Depression: a cognitive perspective. Clin Psychol Rev 2019;69:51-66. 272. Fava GA, Guidi J. The pursuit of euthymia. World Psychiatry 2020;19:40-50. 273. Ryff CD. Psychological well-being revisited. Psychother Psychosom 2014;83:10-28. 274. Carrozzino D, Svicher A, Patierno C et al. The Euthymia Scale: a clinimetric approach. Psychother Psychosom 2019;88:119-21. 275. MacLeod A. Euthymia: why it really does matter. World Psychiatry 2020;19:1-2. 276. Guidi J, Piolanti A, Gostoli S et al. Mental pain and euthymia as transdiag-nostic clinimetric indices in primary care. Psychother Psychosom 2019;88: World Psychiatry 19:3 – October 2020 293252-3. 277. McEwen BS. The untapped power of allostasis promoted by healthy life-style. World Psychiatry 2020;19:57-8. 278. Wood AM, Joseph S. The absence of positive psychological (eudemonic) well-being as a risk factor for depression. J Affect Disord 2010;122:213-7. 279. LeMoult J, Kircanski K, Prasad G et al. Negative self-referential process-ing predicts the recurrence of major depressive episodes. Clin Psychol Sci 2017;5:174-81. 280. De Las Cuevas C, de Leon J. A clinimetric approach for improving the meas-urement of pharmacophobia with replication in two other samples. Psy-chother Psychosom 2019;88:116-8. 281. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depres-sive disorders. J Clin Psychiatry 2008;68(Suppl. E1):4-7.